Join Date
October 2024
Country
Gender
Not Specified
Age
Not Specified
About Kathryn Kwant
Kathryn has 12 years of experience engineering proteins for improved properties. She spent 5 years as a key early scientist at Harpoon Therapeutics, where she developed bispecific immunotherapies and protease activated immunotherapies. She has helped develop multiple drugs that are currently in the clinic to treat various cancers and has multiple patents and patent applications.
Companies & Work
Engage Bio
Engage Bio is developing mRNA immunotherapies to defeat cancer. Our founders have deep experience in immunotherapy development, including four drugs in the clinic, and in building mRNA therapeutics platforms. Our approach is to provide cancer cells with instructions to make and gradually release our drugs within solid tumors. This local therapy allows us to eliminate tumors while sparing healthy distant tissues.
